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 
Abstract² This paper summarizes the experience and the 
lessons learned from the European project PERFORM (A 
sophisticated multi-parametric system FOR the continuous 
effective assessment and monitoring of motor status in 
3DUNLQVRQ¶V GLVHDVH DQG RWKHr neurodegenerative diseases). 
PERFORM is aimed to provide a telehealth system for the 
remote monitoring oI3DUNLQVRQ¶VGLVHDVHSDWLHQWV (PD) at their 
homes. This paper explains the global experience with 
PERFORM. It summarizes the technical performance of the 
system and the feedback received from the patients in terms of 
usability and wearability.  
I. INTRODUCTION 
PERFORM system targets the remote monitoring and 
managemeQWRISDWLHQWVZLWK3DUNLQVRQ¶V'LVHDVH3'. PD 
is one of the most common neurodegenerative disorders. It 
occurs in about 1% of the population over the age of 60 and 
its prevalence increases with age. Advancements in treatment 
for chronic diseases have resulted in reduced length of 
hospital stay, and in some cases, the avoidance of hospital 
visits. Telemedicine brings healthcare delivery to the home 
environment by connecting the patient with medical 
professionals. It is not intended to replace health professional 
care, but rather to enhance the level of care [1].  
The major motor disturbances in PD are bradykinesia 
(i.e. slowed movement), hypokinesia (small amplitude 
movements), resting tremor, rigidity, and postural instability. 
These major motor features of PD are associated with, and 
are largely a result of, the loss of dopaminergic innervation 
of the basal ganglia. Although a genetic predisposition has 
been identified in a subset of patients with PD, several other 
risk factors for PD have been recognized [1-3]. The cause 
and etiology of PD are largely unknown [2±6]. PD is 
typically characterized by severe, unpredictable and abrupt 
changes in the patient motor performance whereby OFF 
periods, characterized by the temporary loss of drugs 
effectiveness, alternate, sometimes within minutes, with ON 
periods, during which the medication effectively attenuate 
motion symptoms. The loss of dopaminergic neurons 
compromises the speed, the automaticity and fluidity of 
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PRYHPHQWV $V WKH GLVHDVH HYROYHV 3' SDWLHQW¶V PRWLRQ
becomes slower and tremoric and the response to medication 
fluctuates along the day (ON-OFF periods). In addition, the 
presence of involuntary movements (dyskinesias) 
deteriorates voluntary movement in advanced state of the 
disease. 
  
Fig. 1. Sensors used for data collection and their posLWLRQRYHUWKHSDWLHQW¶V 
II. CURRENT PRACTICE AND PERFORM APPROACH 
A. Current practice 
Currently, motor assessment in PD is mainly based on 
historical information, home diaries and neurological 
examination during visits to the clinic. These methods 
clearly suffer from many drawbacks: data from these sources 
FDQEHKLJKO\ VXEMHFWLYH WKH\ UHO\RQ WKHSDWLHQW¶VPHPRU\
and perception of his own symptoms and they depend on the 
SK\VLFLDQ¶V H[SHULHQFH RQ WKH ILHOG0RUHRYHUPRVW RI WKH
patients may not be aware of mild symptoms, they may not 
necessarily understand medical terminology, or they may 
unconsciously exaggerate or attenuate symptoms severity. 
Finally, PD can affect short-term memory. In an attempt to 
solve these problems and to find more objective assessments, 
several rating scales have been designed and used. Among 
WKHP WKH 8QLILHG 3DUNLQVRQ¶V GLVHDVH 5DWLQJ 6FDOH
(UPDRS) [7] is the most widely used. This rating scale tries 
to quantify selected symptoms and parkinsonian signs in a 5-
points scoring system (from 0 for no sign, to 4 for a marked 
severity of the sign). Unfortunately, the UPDRS, like any 
other semi-objective rating scale, has several limitations. In 
fact intra and inter-observer inconsistencies and bias by 
subjectivity issues related to the historical information have 
been demonstrated. Moreover, the pattern and severity of PD 
symptoms may vary considerably during the day, while 
clinical rating scales only provide moment-to-moment 
assessments; and finally, measurements of motor functions 
made in the clinic may not accurately reflect the actual 
functional disability experienced by the patients in their daily 
life. All those methods described above provide limited 
information. 
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B. PERFORM system 
PERFORM is a telematic platform for PD remote 
monitoring developed in the last years by a European 
Consortium of SMEs, large companies, Universities and 
research centers [8]. The current status of the project is a 
fully operative prototype which has been tested in three 
different hospitals across Europe: University of Navarra 
Medical School Hospital (Spain), the University of Ioannina 
Hospital (Greece) and the Nuovo Ospedale Civile 
S.Agostino-Estense of Modena (Italy).  
 
Fig. 2. Medication intake screen. The dose and type of pills is indicated by 
the appropriate image in order to help the end user remember what kind of 
medication he/she took and when. By clicking on the prescribed doses the 
user is able to confirm that the medication was taken at the prescribed time 
(or declare the real intake time by moving the pill along the horizontal time 
line). The user can also declare the dosage taken. In order to add a 
medication intake that was not scheduled, the user can click on the empty 
space of the desired medicine rectangle.  
PERFORM platform was composed by a set of wearable 
sensors devices for the recording of the motion signals and a 
set of software algorithms for the signal processing (Fig. 1). 
The hardware was formed by a set of four tri-axial 
accelerometers positioned at each patient limb used to record 
signals from legs and harms; a belt sensor, composed by an 
accelerometer and a gyroscope, used to record body 
movement accelerations and angular rate; and a data logger 
used to receive and store all recorded signals in a SD card. 
All sensors transmit data using Zigbee protocol to the logger 
device, with 62.5 Hz sampling rate before a synchronization 
phase. All accelerometers transmit data at the same time and 
no retransmission of lost packets has been implemented in 
order to save battery. The system is characterized with a 
global dataloss of 1.24±0.58%. 
Apart from the wearable sensor network, each patient 
was provided with touch-screen PC at his/her home. The 
application installed in the PC carries out the signal 
processing tasks. Once the raw data is downloaded from 
logger to the PC, it is automatically processed. This software 
is responsible for the identification and quantification of the 
patient.A customized graphical user interface (GUI) has been 
designed to allow the patients enter other useful information. 
The user could interact with it either with the mouse or with 
the touch screen modality. Using a touch-screen system 
offers interesting benefits in the PERFORM case [9]. 
Touching a visual display of choices requires little thinking 
and it is a form of direct manipulation easier to learn. Touch 
screens have easier hand-eye coordination than mice or 
keyboards and they are the fastest pointing device. 
Besides, the GUI was tested on every phase of the pilots 
DQG UHGHVLJQHG DFFRUGLQJ WR WKH XVHUV¶ IHHGEDFN 7KH
software allows the patients to insert the following 
information:  
x medication intake (kind, dose and time) (Fig. 2)  
x meals (type of food, amount, time) (Fig. 3)  
x PDQ-39. An standard questionnaire for the 
evaluation of physical, emotional and psychosocial 
aspects of Quality of Life (QoL) in PD patients [10].  
The nature unsupervised environments creates a number 
of challenging problems with regards to signals 
interpretation and signals quality validation [11]. Collecting 
this information is essential in order to create a context and 
to make the signal processing outcome useful in this sort of 
environments. In fact, motor behavior strongly depends on 
WKH DVVXPSWLRQ RI WKH PHGLFDWLRQ LQ WKH XVXDO SDWLHQW¶V
dosage) and the metabolism of the drug is influenced by the 
diet (proteins or fats).  
 
Fig. 3 Meals questionnaire screen. Here the patient is able provide 
information about the meals taken during the day. The user can compose 
any of the main meals of the day by dragging selected food products into 
the appropriate containers representing Breakfast, Lunch, Dinner, and 
Supper. Each container can be moved along the timeline presented on the 
bottom of the page. In this way, the patient indicates when the meal was 
taken (the time is shown at the top of the meal container).  
III. METHODS 
A. Data collection 
PERFORM followed an iterative design process. Three 
different phases where designed involving 92 PD patients 
and 20 health subjects. On each phase of the design raw 
signals were collected using the wearable sensor network.  
x Phase I. A preliminary version of the system was 
tested with 20 healthy subjects. Also this initial 
phase was used to test the technical performance of 
the platform in terms of data transmission and 
communication, identify bugs and redesign the 
system. 
x Phase II. The second phase was carried out in the 
hospital under the supervision of the doctors. The 
goal of this phase was to validate not only the 
technical performance of the system but also the 
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clinical compliance of the system. A total number of 
participants of 36 PD patients were involved. 
x Phase IIII: It consisted in the evaluation of final 
PERFORM prototype. In this last phase the final 
version of the system was tested in everyday practice 
DW SDWLHQWV¶ KRPH. The total number of participants 
was 44 PD patients plus 12 patients with 
Parkinsonisms (Parkinsonism is any condition that 
causes a combination of the movement abnormalities 
seen in Parkinson's disease such as tremor, slow 
movement or muscle stiffness). 
B. Inclusion and exclusion criteria 
Patients fulfilling the following criteria were eligible for 
the study: Diagnosis of 3DUNLQVRQ¶V GLVHDVH, ages of 18-85, 
ambulatory and capable of complying with study 
requirements, receiving stable dopaminergic treatment, 
experiencing motor fluctuations, presence of a responsible 
caregiver who can cooperate with patient and Perform Team 
Exclusion Criteria: Dementia, psychosis (simple visual 
hallucinations excluded), significant systemic disease (such 
as: cancer, hepatic or kidney dysfunction, etc.), previous 
Deep Brain Stimulation or Implant of other stimulators   
Before to begin the protocol each patient was offered a 
written description of the study in his/her own language as 
well as an oral explanation of the research expressed in terms 
that would have the best chance of being understood. The 
experimental nature of this study, its inherent risks and 
discomforts, and its potential for improving the treatment of 
PD was discussed. Then clinician obtained informed consent 
and gave a letter with a synopsis of Perform Protocol for 
family doctor to inform him about main issues of the study.  
C. Data processing 
In order to assess the status of the patient the SDWLHQW¶V 
computer was equipped with ad-hoc software for the 
detection and quantification of the PD symptoms. The 
technology used is based on machine learning algorithms; 
specifically in classificators (knowledge about a given 
problem is learnt from examples also called the training 
data). As general approach the raw signal is preprocessed 
with a linear interpolation algorithm in order to fix the 
dataloss holes. Then, the signal is split RXWLQ³HSRFKV´XVLQJ
a slide window (between 1 and 5 seconds length). For each 
³HSRFK´ GLIIHUHQW IHDWXUHV DUH FDOFXODWHG HJ UPV HQWURS\
or range). These features will feed the classificators which 
were previously trained using the UPDRS as reference. Data 
from the Phase II were used to train and validate these 
algorithms. The window length, classificator type and 
features that better fit for each symptom were already 
discussed in detail: tremor [12], [13], levodopa-induced 
dyskinesias [14], [15], bradykinesia [16], [17] and the 
assessment of gait [18]. 
D. 8VHUV¶IHHGEDFNDQGZHDUDELOLW\ 
The evaluation of the system wearability was performed 
with the involvement of a subset of 24 users, 18 males and 6 
females from the Phase IV of the PERFORM pilot. Their age 
ranged between 52 and 76 years old. For the posture 
analysis, all patients were asked to stand up and stay still for 
a couple of minutes, while an observer completed the scoring 
of REBA evaluation based on the posture of trunk, neck, legs 
and arms [19]. Patients were also asked to read a number of 
statements and provide a rating between 0 (low) and 20 
(high), corresponding to their level of agreement with each 
statement with regards to emotions, anxieties and harm 
caused by the system. REBA is a methodology for assessing 
how wearing a computer affects the user in terms of 
physiological energy expenditure, the biomechanical effects 
due to changes in movement patterns, posture and 
perceptions of localized pain and discomfort due to 
musculoskeletal loading, and perceptions of well- being 
through comfort assessment. ,QRUGHU WR HYDOXDWH WKHXVHUV¶
experience with the symptom an informal interview was held 
with the patients in Phase III. 
IV. RESULTS 
A. Technical performance 
For each symptom, a dedicated algorithm processes the 
relevant signals, detects the symptom episode and quantifies 
it into a severity scale from 0 to 4, according to the UPDRS 
VFDOH IRU3'¶VSDWLHQWV$ERXW WKH WHFKQLFDOSHUIRUPDQFHRI
the system it shows an accuracy of 93.73% for the 
classification of levodopa induced diskynesias (LID) severity 
[14], a 86% of bradykinesia severity [17] and 87 % for 
tremor [12]. As well as it has developed a special module for 
the assessment of the gait parameters i.e. step frequency, 
velocity, arm swing frequency and entropy of the gait signal 
(entropy is a good measure of the randomness of the signal 
and it is an excellent discriminator of the On/Off status) [18].  
These results were obtained using support vector machines 
and decision trees (depending on the symptoms). 
B. Users feedback  
After the chat with the patients it is possible to conclude 
that the experience with the touch-screen PC was well 
accepted; no patient reported problems using it and all of 
them were able to carry out the monitoring sessions with the 
instructions provided. Most of the issues reported from the 
patients were fixed with minor modifications of the system 
91.5%. Most of the changes (61.11%) where related to a bad 
implementation of the software i.e. problems with the 
webcam drivers, microphone drivers and software bugs. The 
other 38.89% of the patients complains where related to 
usability problems e.g. text too small or a not enough 
intuitive screen. 
C. System wearability  
The majority of the patients did not feel any 
discomfort/pain at most of their body parts. Only few 
patients (8 out of 24 patients) felt extremely week 
discomfort/pain at overall assessment of their body. None of 
the patients had the perception of any kind of harm (e.g. 
headache, pain, itching, irritation, etc.) caused by the 
devices. The interview revealed some emotional and 
appearance issues of a group of patients (6 out of 24). These 
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patients had some concerns about the impression they make 
to others when wearing the devices. They would feel much 
more comfortable if the devices were not visible or if they 
had to wear them only at home. All participants agreed that 
the provided solution did not obstruct them in everyday 
activities neither limited their activities in an effective way. 
The only concern expressed by a number of patients was 
regarding the proper attachment of the current appliance. 
The effect of the wearable device to patients was always 
³ORZ´FRQILUPLQJWKHZHDUDELOLW\RIWKHV\VWHP 
V. DISCUSSION 
Telehealth is more than using wearable sensors at patients¶
home, especially, when we are talking about chronic disease 
management. It means to involve patients and caregivers in 
the healthcare path and shift their role from a passive 
position to an active position. And in consequence, transform 
them in main actors of the healthcare process. 
The first and most obvious reason is that home telehealth 
systems need the participation and cooperation of patients 
and caregivers to work efficiently. In the PERFORM context 
the algorithms developed have achieved a good accuracy. 
Nevertheless, in order to achieve a good understanding of the 
disease in the patient and to build a profile of the patient, 
context information (i.e. food and medication intakes) is 
required. That means it is needed to invest time and effort in 
the patient and caregiver training, to capacitate them with the 
adequate education to use the system properly as well as 
follow the best practices for GUI design. Moreover, it is 
important to translate them the importance of the self-
assessment and the responsibilities they should take care.  
VI. CONCLUSION 
From the technical point of view, PERFORM has shown 
the feasibility of using wearable accelerometers in 
combination with machine learning algorithms in order to 
perform a continuous monitoring of PD patients. Also, 
patients have shown a good acceptance of the system. As it 
was discussed in this work, the main challenges for these 
sorts of systems are the wide range of symptoms, the 
variability of the symptoms and also the uncertainty working 
on unsupervised environments. Due to these reasons get the 
patients and caregivers involvement should be one the first 
issues to address during the design process.  
Next steps must prove the feasibility of the system in a 
large-scale, long-term and randomized controlled trial in 
order to show the feasibility of the system for its deployment 
in the clinical practice. 
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